23andMe (NASDAQ:ME – Get Rating) will release its earnings data after the market closes on Monday, August 8th. 23andMe has set its FY 2023 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.
23andMe (NASDAQ:ME – Get Rating) last released its quarterly earnings data on Thursday, May 26th. The company reported -0.13 EPS for the quarter. The company had revenue of 100.56 million during the quarter, compared to analysts’ expectations of 102.79 million. 23andMe had a negative return on equity of 25.41% and a negative net margin of 79.99%. The business’s revenue was up 13.5% on a year-over-year basis.
23andMe Price Performance
Shares of ME stock opened at 3.64 on Friday. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -5.52 and a beta of 1.53. The stock has a 50 day simple moving average of 2.72 and a 200-day simple moving average of 3.41. 23andMe has a 1-year low of 2.12 and a 1-year high of 13.68.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of brokerages have issued reports on ME. Citigroup cut their target price on 23andMe from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Friday, May 27th. Credit Suisse Group lowered their price target on 23andMe from $11.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, May 27th.
23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.